Your Messages Inbox
Your Article Summary
See Latest ArticlesFDA approves Promacta (eltrombopag), the first oral medication to increase platelet production for people with serious blood disorder
GlaxoSmithKline, 11/21/08
GlaxoSmithKline announced that the United States Food and Drug Administration (FDA) granted accelerated approval for Promacta (eltrombopag) for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. The approval is a significant milestone for eltrombopag and the ITP community, as eltrombopag is the first oral thrombopoietin (TPO) receptor agonist approved for adult patients with chronic ITP. GSK expects eltrompopag to be available next week.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Recombinant Human Erythropoietin, Epogin Injection
Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09
Synthon announces European approvals for Raloxifene
Synthon, 12/08/09
US FDA approves SEROQUEL for the pediatric treatment of schizophrenia and bipolar mania
AstraZeneca, 12/07/09
Article Search
Sponsor